Trial Profile
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared With Sevelamer Carbonate in Dialysis Patients With Hyperphosphataemia. Extension Study for Protocol PA-CL-05A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Vifor
- 29 May 2018 Results of post-hoc analysis from both parent (NCT01324128) and extension (NCT01464190) study assessing the effects serum phosphate control and FGF-23 levels with sucroferric oxyhydraoxide and sevelamer on CKD-MBD parameters among dialysis patients who completed 1 year of treatment with sucroferric oxyhydroxide or sevelamer published in the Nephrology Dialysis Transplantation
- 23 Feb 2017 Results (n=1055) of both parent and extension study assessing one year efficacy and safety published in the Nephrology Dialysis Transplantation.
- 23 Jun 2016 Results of post-hoc analysis of patients who completed 52 weeks of continuous treatment (n = 549) from this trial and its parent trial (NCT01324128) published in the Nephrology Dialysis Transplantation